Emerging Patent Landscape for Gene Therapy as a Potential Cure for COVID-19
Table 1
RNAi-based treatments for COVID-19 in clinical and preclinical trials.
Developer/researcher
Product description
Phase
Anticipated next steps
Mateon Therapeutics
Ot-101, a TGF-beta antisense drug candidate
Clinical
Phase II study IND submitted to FDA on April 27, 2020; phase II trials approved in Peru, Nov 2020
AIM Immunotech/National Institute of Infectious Diseases in Japan/Roswell Park Comprehensive Cancer Center
Ampligen (rintatolimod)
Preclinical
Phase I/II trial in combination with interferon alfa-2b, in cancer patients with COVID-19 not yet recruiting July 2020; phase I/II clinical trials for COVID-19 NCT04379518
Neurimmune/Ethris
Inhaled mRNA
Preclinical
Phase I to start Q4 2020
Sarepta Therapeutics/US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Antisense oligonucleotides, peptide conjugated
Preclinical
Clinical trials for COVID-19
Sirnaomics
RNAi, TESTING 150 RNAiS
Preclinical
Clinical trials for COVID-19
VIR Biotech/Alnylam Pharmaceuticals
VIR-2703 (ALN-COV) siRNA candidate
Preclinical
Clinical trials for COVID-19; phase I to start by the end of 2020
